HS Code:
Hydralazine hydrochloride (HS Code: 29339900) is a pharmaceutical compound classified under heterocyclic compounds with nitrogen hetero-atoms. It is primarily used as an antihypertensive drug to treat high blood pressure and heart failure. As a vasodilator, it works by relaxing blood vessels, allowing blood to flow more easily. This product is traded globally in both raw material and finished pharmaceutical forms, with significant demand in markets with aging populations and high incidences of cardiovascular diseases.
Total Trade Volume
USD 45 million
Data from 2022
Source
UN Comtrade Database, International Trade Centre (ITC)
Average Rate
6.5%
Highest Rate
12% (applied by certain developing countries to protect domestic industries)
Lowest Rate
0% (under free trade agreements such as USMCA and EU-India FTA)
Rising demand due to increasing cardiovascular diseases
Increased export opportunities for major producers like India and China as global healthcare needs grow
2022
Shift toward generic drug production
Reduced costs and increased accessibility in developing markets, boosting trade volumes
2021
Stricter regulatory frameworks
Higher compliance costs for exporters, potentially limiting smaller players
2020
The European Union introduced stricter guidelines for the importation of active pharmaceutical ingredients (APIs), including Hydralazine hydrochloride, requiring additional documentation and quality checks.
March 2023
Increased compliance costs for exporters to the EU, potentially affecting trade volumes from non-EU countries like India and China.
India's Production Linked Incentive (PLI) scheme for pharmaceuticals has incentivized domestic production of APIs like Hydralazine hydrochloride, reducing reliance on imports.
January 2022
Strengthened India's position as a leading exporter, likely increasing its global market share.
The US Food and Drug Administration approved multiple generic versions of Hydralazine hydrochloride, increasing market competition.
September 2022
Downward pressure on prices, benefiting importers but challenging high-cost producers.